See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
The effect of renal impairment on the pharmacokinetics and safety of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor
The effect of renal impairment on the pharmacokinetics and safety of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor
Utility of coproporphyrin-I determination in first-in-human study for early evaluation of OATP1B inhibitory potential based on investigation of ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor
Utility of coproporphyrin-I determination in first-in-human study for early evaluation of OATP1B inhibitory potential based on investigation of ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor
A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations
A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations
Cefiderocol for injection: compatibility testing using the MINI-BAG plus container system and the VIAL-MATE adaptor
Cefiderocol for injection: compatibility testing using the MINI-BAG plus container system and the VIAL-MATE adaptor
Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program
Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program